Cassava Sciences Inc.
6801 N. Capital of Texas Highway Building 1
Austin
TX
78731
United States
Website: https://www.cassavasciences.com/
285 articles about Cassava Sciences Inc.
-
Cassava Sciences Announces New $2.5 Million Research Grant Award from National Institutes of Health
4/23/2020
- Grant Will Support an On-going Clinical Evaluation of Lead Investigational Drug PTI-125 in Alzheimer’s Disease -
-
Cassava Sciences Announces Full-year 2019 Financial Results and Anticipated Key Milestones for 2020
3/26/2020
Cassava Sciences,, today announced financial results for the year ended December 31, 2019 and provided corporate milestones for 2020.
-
Cassava Sciences Announces Initiation of an Open-Label Study to Evaluate PTI-125 in Patients with Alzheimer’s DiseaseApproximately 100 Study Participants Will Receive PTI-125 For 12 Months
3/25/2020
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the initiation of an open-label extension study to evaluate PTI-125 in patients with Alzheimer’s disease. The Company’s lead investigational drug, PTI-125, seeks to improve both neurodegeneration and neuroinflammation in patients with Alzheimer’s disease. “We believe the ability of our drug to improve multiple function
-
Cassava Sciences Announces Clinical Update and Business Progress Across Neuroscience Pipeline
3/19/2020
Cassava Sciences, Inc. today announced clinical updates and business progress across its pipeline of product candidates under development.
-
Cassava Sciences Announces Phase 2a Study of PTI-125 Published in The Journal of Prevention of Alzheimer’s Disease (JPAD)
2/11/2020
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that The Journal of Prevention of Alzheimer’s Disease (JPAD), a peer-reviewed journal for the research community, published results from the Company’s Phase 2a study demonstrating that its lead drug candidate, PTI-125, reduced biomarkers of disease in Alzheimer’s patients.
-
Cassava Sciences Announces Additional Positive Phase 2a Clinical Data in Alzheimer’s Disease at CTAD 2019
12/5/2019
New Data Shows Clinical Evidence of Target Engagement and Target Validation
-
Cassava Sciences Announces Recent Clinical Highlights and Third Quarter 2019 Financial Results
10/29/2019
Phase 2a Study Showed Statistically Significant Decreases (p<0.001) in Clinical Biomarkers of Alzheimer’s Disease
-
Cassava Sciences’ Clinical Results in Alzheimer’s Selected as Late-Breaking News at CTAD 2019
10/24/2019
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, today announced that clinical results of its Phase 2a study of PTI-125 have been selected as a late-breaking oral presentation by the 12thInternational Conference onClinical Trials on Alzheimer’s Disease (CTAD). CTAD is a prestigious annual conference focused on Alzheimer’s research and development and takes place this year in San Diego, CA, on December 4-7th, 2019.
-
Investors are not happy after Austin, Texas-based Pain Therapeutics announced that it was no closer to seeing its drug candidate Remoxy ER, an abuse-deterrent, extended-release gel formulation of oxycodone, approved by the U.S. Food and Drug Administration.
-
Texas-based Pain Therapeutics is urging the FDA to reconsider the Complete Response Letter it issued in August for the company’s opioid-treatment, Remoxy. Representatives from Pain Therapeutics will meet with the FDA on Jan. 31. 2019 to discuss the request, the company announced late Monday.
-
Pain Therapeutics Announces $3.5 Million NIH Grant Award to Study Alzheimer’s Disease
10/4/2018
NIH Grant Will Enable Clinical Tests of PTI-125 in Patients with Alzheimer’s Disease
-
Pain Therapeutics Announces Investor Call to Provide Strategic UpdateCall to be Held on Thursday, October 4th, 10:00 AM Eastern Time
10/2/2018
Pain Therapeutics, Inc. today announced that it will host a live conference call to provide a strategic update regarding its business, its science and its pipeline.
-
The biotech industry is fast-moving and dynamic, and staying on top of all the news can be hard for our busy readers. Here’s a look back at some of the top stories you may have missed this month.
-
DURECT's Licensee Pain Therapeutics Receives Complete Response Letter from FDA for REMOXY® ER (oxycodone) Extended-Release Capsules CII
8/6/2018
DURECT Corporation announced that its licensee, Pain Therapeutics reported that it received a Complete Response Letter from the U.S. FDA for Pain Therapeutics' New Drug Application (NDA) for REMOXY® ER (oxycodone) extended-release capsules CII, which concluded that "The data submitted in [the] NDA do not support the conclusion that the benefits of [REMOXY] Extended-Release Capsules outweigh the risks."
-
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter—basically a rejection—to Austin, Texas-based Pain Therapeutics for Remoxy ER for pain.
-
Now that July is over, the U.S. Food and Drug Administration (FDA) appears to be back in full swing with a full docket of drug decisions to make. There are four therapeutics with PDUFA dates this week involving six biopharma companies. Here’s a look.
-
Pain Therapeutics stock plunged 70 percent after a U.S. Food and Drug Administration (FDA) advisory committee voted 14 to 3 against approval of its Remoxy ER for severe pain.
-
DURECT Announces FDA Advisory Committee Meeting for REMOXY® ER
3/20/2018
DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE), reported yesterday that the U.S. Food and Drug Administration (FDA) will hold an Advisory Committee Meeting to discuss the New Drug Application (NDA) for REMOXY ER (extended release oxycodone CII).
-
Pain Therapeutics Resubmits NDA for REMOXY ER, an Abuse-Deterrent, Extended-Release Drug Candidate for the Treatment of Chronic Pain
2/13/2018
The Company expects a six-month review cycle by FDA.
-
Pain Therapeutics Reports 2017 Financial Results and Corporate Update
2/5/2018
Net loss in 2017 was $11.9 million, or $1.82 per share, compared to a net loss in 2016 of $14.9 million, or $2.28 per share.